HC Wainwright reaffirmed their buy rating on shares of Apricus Biosciences, Inc (NASDAQ:APRI) in a research report released on Wednesday, August 30th. The firm currently has a $5.00 target price on the stock.
Separately, Zacks Investment Research cut shares of Apricus Biosciences from a hold rating to a sell rating in a research report on Tuesday, June 27th.
Shares of Apricus Biosciences (NASDAQ:APRI) traded up 4.55% on Wednesday, reaching $1.84. The company had a trading volume of 256,760 shares. Apricus Biosciences has a 12 month low of $0.26 and a 12 month high of $4.07. The company’s 50-day moving average is $1.50 and its 200 day moving average is $1.48. The firm has a market capitalization of $23.52 million, a PE ratio of 3.07 and a beta of 0.55.
Apricus Biosciences (NASDAQ:APRI) last announced its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. Equities analysts forecast that Apricus Biosciences will post ($0.81) earnings per share for the current year.
WARNING: This report was posted by BBNS and is the property of of BBNS. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://baseballnewssource.com/markets/apricus-biosciences-inc-apri-given-a-5-00-price-target-by-hc-wainwright-analysts/1566527.html.
Apricus Biosciences Company Profile
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with our FREE daily email newsletter.